- Home
- SELF vs GANX Comparison
SELF vs GANX Comparison
Compare SELF & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SELF
- GANX
- Stock Information
- Founded
- SELF 1983
- GANX 2017
- Country
- SELF United States
- GANX United States
- Employees
- SELF N/A
- GANX N/A
- Industry
- SELF Real Estate Investment Trusts
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- SELF Real Estate
- GANX Health Care
- Exchange
- SELF Nasdaq
- GANX Nasdaq
- Market Cap
- SELF 58.8M
- GANX 69.0M
- IPO Year
- SELF N/A
- GANX 2021
- Fundamental
- Price
- SELF $5.15
- GANX $1.75
- Analyst Decision
- SELF
- GANX Strong Buy
- Analyst Count
- SELF 0
- GANX 5
- Target Price
- SELF N/A
- GANX $8.20
- AVG Volume (30 Days)
- SELF 36.6K
- GANX 555.0K
- Earning Date
- SELF 11-07-2025
- GANX 08-12-2025
- Dividend Yield
- SELF 5.61%
- GANX N/A
- EPS Growth
- SELF 9.99
- GANX N/A
- EPS
- SELF 0.22
- GANX N/A
- Revenue
- SELF $12,707,884.00
- GANX N/A
- Revenue This Year
- SELF N/A
- GANX N/A
- Revenue Next Year
- SELF N/A
- GANX N/A
- P/E Ratio
- SELF $23.87
- GANX N/A
- Revenue Growth
- SELF 4.08
- GANX N/A
- 52 Week Low
- SELF $4.78
- GANX $1.00
- 52 Week High
- SELF $5.89
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- SELF 45.23
- GANX 49.48
- Support Level
- SELF $5.11
- GANX $1.55
- Resistance Level
- SELF $5.51
- GANX $2.05
- Average True Range (ATR)
- SELF 0.14
- GANX 0.16
- MACD
- SELF -0.00
- GANX -0.01
- Stochastic Oscillator
- SELF 25.00
- GANX 38.46
About SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.